| Symbol | SGHT |
|---|---|
| Name | SIGHT SCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medical/Dental Instruments |
| Address | 4040 CAMPBELL AVENUE,SUITE 100, MENLO PARK, California, 94025, United States |
| Telephone | +1 877 266-1144 |
| Fax | — |
| — | |
| Website | https://www.sightsciences.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001531177 |
| Description | Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segments product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The companys Dry Eye segments product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment. Additional info from NASDAQ: |
TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease
Read moreRashid Kashif 🟢 acquired 181.8K shares of Sight Sciences, Inc. (SGHT) Transaction Date: Aug 10, 2026 | Filing ID: 355783
Read moreNew Form 3 - Sight Sciences, Inc. <b>Filed:</b> 2026-08-18 <b>AccNo:</b> 0001193125-26-355781 <b>Size:</b> 21 KB
Read more📋 HAYDEN JEREMY B. (Ex-Officer) plans to sell 12K shares of Sight Sciences, Inc. (at $8.14 each, total $98K) Filed: Aug 17, 2026 | ID: 006121
Read more📋 HAYDEN JEREMY B. (Ex-Officer) plans to sell 2K shares of Sight Sciences, Inc. (at $8.30 each, total $21K) Filed: Aug 13, 2026 | ID: 005984
Read more📋 HAYDEN JEREMY B. (Officer) plans to sell 21K shares of Sight Sciences, Inc. (at $7.93 each, total $166K) Filed: Aug 11, 2026 | ID: 005895
Read more(99% Neutral) SIGHT SCIENCES, INC. (SGHT) Announces New Board Appointment
Read moreSight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems
Read moreSight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System
Read moreSight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07579156 | TearCare in Young Adults | Na | Meibomian Gland Dysfunction (Disorder) | Not_Yet_Recruiting | 2026-08-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT07365735 | TearCare MGX™ System With and Without Warming Hold | Na | Meibomian Gland Dysfunction (Disorder) | Completed | 2026-03-17 | 2026-05-19 | ClinicalTrials.gov |
| NCT06991270 | OMNI 3.1 Surgical System in Subjects With Primary Open-Angle Glaucoma | Na | Primary Open Angle Glaucoma | Recruiting | 2026-02-01 | 2027-05-01 | ClinicalTrials.gov |
| NCT06948773 | A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and … | Na | Primary Open Angle Glaucoma | Active_Not_Recruiting | 2025-05-21 | 2026-09-30 | ClinicalTrials.gov |
| NCT06407973 | A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatme… | Phase4 | Primary Open Angle Glaucoma | Terminated | 2024-08-21 | 2025-01-20 | ClinicalTrials.gov |
| NCT04658095 | Study of OMNI Surgical System and iStent for Eyes With OAG (Trident) | Na | Glaucoma, Open-Angle | Terminated | 2022-01-11 | 2022-11-18 | ClinicalTrials.gov |
| NCT05044793 | A Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical S… | — | Glaucoma, Open-Angle | Completed | 2021-09-01 | 2023-08-21 | ClinicalTrials.gov |
| NCT04872348 | An Observational Multicenter Clinical Study To Assess The Safety And Effectiven… | — | Glaucoma, Open-Angle | Completed | 2021-07-01 | 2023-11-02 | ClinicalTrials.gov |
| NCT04795752 | Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs … | Na | Dry Eye | Completed | 2021-04-28 | 2024-09-23 | ClinicalTrials.gov |
| NCT04616573 | A Post-market Study Of Use Of The OMNI® Surgical System In Open Angle Glaucoma | Na | Glaucoma, Open-Angle | Terminated | 2020-11-13 | 2021-01-20 | ClinicalTrials.gov |
| NCT04465630 | A Prospective, Multicenter Study of the OMNI® Surgical System in Pseudophakic E… | Na | Glaucoma, Open-Angle | Terminated | 2020-06-19 | 2021-03-02 | ClinicalTrials.gov |
| NCT03861169 | Study of OMNI System in OAG (GEMINI) | Na | Open Angle Glaucoma | Completed | 2019-03-11 | 2021-05-04 | ClinicalTrials.gov |
| NCT03857919 | TearCare System to Treat Dry Eye Disease | Na | Dry Eye | Completed | 2019-03-03 | 2020-12-18 | ClinicalTrials.gov |
| NCT03804502 | Pilot Study of TearCare System - Long-Term Extension | Na | Dry Eye Syndromes | Completed | 2018-12-17 | 2019-05-21 | ClinicalTrials.gov |
| NCT03588624 | Study of the TearCare System in Dry Eye Disease | Na | Dry Eye | Completed | 2018-07-12 | 2018-11-08 | ClinicalTrials.gov |
| NCT03502447 | Randomized Study of the Safety and Effectiveness of the TearCare System for the… | Na | Dry Eye Syndromes | Terminated | 2018-04-20 | 2018-12-04 | ClinicalTrials.gov |
| NCT02928289 | Safety and Effectiveness of the Sight Sciences VISCO™360 Versus SLT in Primary … | Na | Open-Angle Glaucoma | Terminated | 2017-01-23 | 2019-01-17 | ClinicalTrials.gov |
| NCT03006978 | A Pilot Study of the TearCare System in Adults With Dry Eye Disease | Na | Dry Eye | Completed | 2017-01-01 | 2018-03-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Helix Surgical System | Other | Approved | Primary Open Angle Glaucoma | ACTIVE_NOT_RECRUITING | NCT06948773 |
| localized heat therapy | Drug | Approved | Meibomian Gland Dysfunction (Disorder) | COMPLETED | NCT07365735 |
| TearCare® | Other | Approved | Meibomian Gland Dysfunction (Disorder) | NOT_YET_RECRUITING | NCT07579156 |
| TearCare® | Other | Approved | Meibomian Gland Dysfunction (Disorder) | NOT_YET_RECRUITING | NCT07579156 |
| TearCare® | Other | Approved | Meibomian Gland Dysfunction (Disorder) | NOT_YET_RECRUITING | NCT07579156 |
| TearCare® | Other | Approved | Meibomian Gland Dysfunction (Disorder) | NOT_YET_RECRUITING | NCT07579156 |
| TearCare® | Other | Approved | Meibomian Gland Dysfunction (Disorder) | NOT_YET_RECRUITING | NCT07579156 |
| TearCare® | Other | Approved | Meibomian Gland Dysfunction (Disorder) | NOT_YET_RECRUITING | NCT07579156 |
| OMNI® Surgical System | Other | Preclinical | Glaucoma, Open-Angle | COMPLETED | NCT04872348 |
| OMNI® Surgical System | Other | Approved | Glaucoma, Open-Angle | TERMINATED | NCT04465630 |
| iStent inject | Other | Approved | Glaucoma, Open-Angle | TERMINATED | NCT04616573 |
| OMNI® Surgical System | Other | Approved | Glaucoma, Open-Angle | TERMINATED | NCT04616573 |
| Transluminal viscoelastic delivery and trabeculotomy | Other | Approved | Open Angle Glaucoma | COMPLETED | NCT03861169 |
| OMNI® Surgical System | Other | Preclinical | Glaucoma, Open-Angle | COMPLETED | NCT05044793 |
| Latanoprost plus adjunctive glaucoma medication | Drug | Phase PHASE4 | Primary Open Angle Glaucoma | TERMINATED | NCT06407973 |
| OMNI Surgical System | Other | Phase PHASE4 | Primary Open Angle Glaucoma | TERMINATED | NCT06407973 |
| Helix Surgical System | Other | Approved | Primary Open Angle Glaucoma | RECRUITING | NCT06948773 |
| TearCare | Other | Approved | Dry Eye | COMPLETED | NCT03588624 |
| Warm Compress and Lid Massage | Other | Approved | Dry Eye Syndromes | TERMINATED | NCT03502447 |
| TearCare | Other | Approved | Dry Eye Syndromes | TERMINATED | NCT03502447 |
| LipiFlow | Other | Approved | Dry Eye | COMPLETED | NCT03857919 |
| TearCare | Other | Approved | Dry Eye | COMPLETED | NCT03857919 |
| Warm Compress | Other | Approved | Dry Eye | COMPLETED | NCT03006978 |
| TearCare | Other | Approved | Dry Eye | COMPLETED | NCT03006978 |
| Canaloplasty | Other | Approved | Glaucoma, Open-Angle | TERMINATED | NCT04658095 |
| iStent inject | Other | Approved | Glaucoma, Open-Angle | TERMINATED | NCT04658095 |
| Canaloplasty and trabeculotomy with the OMNI system. | Other | Approved | Glaucoma, Open-Angle | TERMINATED | NCT04658095 |
| TearCare | Other | Approved | Dry Eye Syndromes | COMPLETED | NCT03804502 |
| Selective Laser Trabeculoplasty (SLT) | Other | Approved | Open-Angle Glaucoma | TERMINATED | NCT02928289 |
| VISCO360 ab interno canaloplasty surgery | Procedure | Approved | Open-Angle Glaucoma | TERMINATED | NCT02928289 |
| Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion | Other | Approved | Dry Eye | COMPLETED | NCT04795752 |
| TearCare System | Other | Approved | Dry Eye | COMPLETED | NCT04795752 |
| OMNI 3.0 Surgical System | Other | Approved | Primary Open Angle Glaucoma | RECRUITING | NCT06991270 |
| localized heat therapy | Drug | Approved | Meibomian Gland Dysfunction (Disorder) | ACTIVE_NOT_RECRUITING | NCT07365735 |
| localized heat therapy | Drug | Approved | Meibomian Gland Dysfunction (Disorder) | ACTIVE_NOT_RECRUITING | NCT07365735 |
| localized heat therapy | Drug | Approved | Meibomian Gland Dysfunction (Disorder) | ACTIVE_NOT_RECRUITING | NCT07365735 |
| localized heat therapy | Drug | Approved | Meibomian Gland Dysfunction (Disorder) | ACTIVE_NOT_RECRUITING | NCT07365735 |
| localized heat therapy | Drug | Approved | Meibomian Gland Dysfunction (Disorder) | ACTIVE_NOT_RECRUITING | NCT07365735 |
| localized heat therapy | Drug | Approved | Meibomian Gland Dysfunction (Disorder) | ACTIVE_NOT_RECRUITING | NCT07365735 |
| localized heat therapy | Drug | Approved | Meibomian Gland Dysfunction (Disorder) | ACTIVE_NOT_RECRUITING | NCT07365735 |
| localized heat therapy | Drug | Approved | Meibomian Gland Dysfunction (Disorder) | ACTIVE_NOT_RECRUITING | NCT07365735 |
| localized heat therapy | Drug | Approved | Meibomian Gland Dysfunction (Disorder) | ACTIVE_NOT_RECRUITING | NCT07365735 |
| localized heat therapy | Drug | Approved | Meibomian Gland Dysfunction (Disorder) | ACTIVE_NOT_RECRUITING | NCT07365735 |
| localized heat therapy | Drug | Approved | Meibomian Gland Dysfunction (Disorder) | ACTIVE_NOT_RECRUITING | NCT07365735 |
| localized heat therapy | Drug | Approved | Meibomian Gland Dysfunction (Disorder) | ACTIVE_NOT_RECRUITING | NCT07365735 |
| localized heat therapy | Drug | Approved | Meibomian Gland Dysfunction (Disorder) | ACTIVE_NOT_RECRUITING | NCT07365735 |
| localized heat therapy | DEVICE | Approved | Meibomian Gland Dysfunction (Disorder) | NOT_YET_RECRUITING | NCT07365735 |
| OMNI 3.0 Surgical System | DEVICE | Approved | Primary Open Angle Glaucoma | RECRUITING | NCT06991270 |
| Helix Surgical System | DEVICE | Approved | Primary Open Angle Glaucoma | RECRUITING | NCT06948773 |
| Latanoprost plus adjunctive glaucoma medication | DRUG | Phase PHASE4 | Primary Open Angle Glaucoma | TERMINATED | NCT06407973 |
| OMNI Surgical System | DEVICE | Phase PHASE4 | Primary Open Angle Glaucoma | TERMINATED | NCT06407973 |
| Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion | DRUG | Approved | Dry Eye | COMPLETED | NCT04795752 |
| TearCare System | DEVICE | Approved | Dry Eye | COMPLETED | NCT04795752 |
| Canaloplasty | DEVICE | Approved | Glaucoma, Open-Angle | TERMINATED | NCT04658095 |
| Canaloplasty and trabeculotomy with the OMNI system. | DEVICE | Approved | Glaucoma, Open-Angle | TERMINATED | NCT04658095 |
| iStent inject | DEVICE | Approved | Glaucoma, Open-Angle | TERMINATED | NCT04658095 |
| OMNI® Surgical System | DEVICE | Preclinical | Glaucoma, Open-Angle | COMPLETED | NCT05044793 |
| Transluminal viscoelastic delivery and trabeculotomy | DEVICE | Approved | Open Angle Glaucoma | COMPLETED | NCT03861169 |
| LipiFlow | DEVICE | Approved | Dry Eye | COMPLETED | NCT03857919 |
| Warm Compress and Lid Massage | DEVICE | Approved | Dry Eye Syndromes | TERMINATED | NCT03502447 |
| Warm Compress | DEVICE | Approved | Dry Eye | COMPLETED | NCT03006978 |
| TearCare | DEVICE | Approved | Dry Eye | COMPLETED | NCT03857919 |
| Selective Laser Trabeculoplasty (SLT) | DEVICE | Approved | Open-Angle Glaucoma | TERMINATED | NCT02928289 |
| VISCO360 ab interno canaloplasty surgery | DEVICE | Approved | Open-Angle Glaucoma | TERMINATED | NCT02928289 |